SeQure Dx offers a portfolio of proprietary off-target analysis platforms to help the gene editing and cell therapy industry evaluate potential off-target effects of their therapeutic candidates. Our NoteSeQ and ScopeSeQ platforms enable our partners to address all of their off-target needs spanning the spectrum of preclinical development, whether nominating potential off-target sites to select a lead candidate or confirming their off-target profile for IND-filing.